IGF-DES

IGF-DES is a truncated, synthetic analog of Insulin-like Growth Factor-1 (IGF-1), lacking the first three N-terminal amino acids: glutamic acid, glycine, and proline. This modification:

  • Increases IGF-1 receptor binding affinity ~10x compared to native IGF-1
  • Reduces half-life to 20–30 minutes (versus several hours for native IGF-1)
  • Bypasses IGF-binding proteins (IGFBPs), ensuring 100% bioavailability at the injection site
  • Muscle Growth: Targeted hypertrophy due to 10x receptor binding affinity
  • Recovery & Repair: Accelerated tissue repair, tendon and ligament healing, fibroblast proliferation
  • Satellite Cell Activation: Enhanced stem cell activation for long-term muscle density
  • Protein Synthesis: mTOR pathway activation improves anabolic protein production
  • Insulin Sensitivity: 2–3x more potent than native IGF-1 in glucose regulation
  • Angiogenesis: Promotes local blood vessel formation for nutrient delivery
  • Post-Workout Recovery: Reduces soreness, speeds recovery from exercise-induced microtrauma
  • Neuroprotection: Supports neuronal survival and recovery after injury
  1. Guan J, et al. (1996). The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins. Endocrinology, 137(3), 893-898. DOI
  2. Adams GR, et al. (1998). Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol, 84(5), 1716-1722. DOI
  3. Yoshida T, et al. (2020). Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells, 9(9), 1970. DOI
  4. Ge L, et al. (2022). Research Progress on Neuroprotection of Insulin-like Growth Factor-1 towards Glutamate-Induced Neurotoxicity. Cells, 11(4), 666. DOI
  5. Philippou A, et al. (2016). Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Neurological Disorders. Front Endocrinol, 7, 103. DOI

$98.00

Per Unit
In stock

Free Shipping on All Orders $1000+